Estrogen or raloxifene during postmenopausal weight loss: Adiposity and cardiometabolic outcomes

Obesity

Volumn 22, Issue 4, 2014, Pages 1024-1031

  Van Pelt, R E ^a   Gozansky, W S ^b   Wolfe, P ^c   Kittelson, J M ^c   Jankowski, C M ^a,c   Schwartz, R S ^a   Kohrt, W M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; TRIACYLGLYCEROL; ESTROGEN; GLUCOSE BLOOD LEVEL; INSULIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDURANCE TRAINING; ENERGY EXPENDITURE; ESTRADIOL BLOOD LEVEL; EXERCISE INTENSITY; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPOPROTEIN BLOOD LEVEL; MEDICATION COMPLIANCE; OBESITY; PATIENT COMPLIANCE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; DRUG EFFECTS; ENERGY METABOLISM; ESTROGEN THERAPY; EXERCISE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED;

ADIPOSITY; AGED; BLOOD GLUCOSE; BODY COMPOSITION; ENERGY METABOLISM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EXERCISE; FEMALE; HUMANS; INSULIN; LIPIDS; MIDDLE AGED; OBESITY; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84897374240     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20653     Document Type: Article

References (40)

1. Björntorp P,. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 1997; 13: 795-803.
2. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR,. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes 2008; 32: 949-958.
3. Lobo RA,. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008; 60: 10-18.
4. Polotsky HN, Polotsky AJ,. Metabolic implications of menopause. Semin Reprod Med 2010; 28: 426-434.
5. Kristensen K, Pedersen SB, Vestergaard P, Mosekilde L, Richelsen B,. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol 1999; 163: 55-62.
6. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR,. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001; 39: 125-132.
7. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE,. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8: 538-554.
8. Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv 2013; 68: 467-481.
9. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009; 119: 922-930.
10. Gozansky WS, Van Pelt RE, Jankowski CM, Schwartz RS, Kohrt WM,. Protection of bone mass by estrogens and raloxifene during exercise-induced weight Loss. J Clin Endocrinol Metab 2005; 90: 52-59.
11. Donnelly JE, Smith BK,. Is exercise effective for weight loss with ad libitum diet? Energy balance, compensation, and gender differences. Exerc Sport Sci Rev 2005; 33: 169-174.
12. Van Pelt RE, Jankowski CM, Gozansky WS, Schwartz RS, Kohrt WM,. Lower-body adiposity and metabolic protection in postmenopausal women. J Clin Endocrinol Metab 2005; 90: 4573-4578.
13. Kohrt WM, Ehsani AA, Birge Jr, SJ,. HRT preserves increases in bone mineral density and reductions in body fat after a supervised exercise program. J Appl Physiol 1998; 84: 1506-1512.
14. Witte MM, Resuehr D, Chandler AR, Mehle AK, Overton JM,. Female mice and rats exhibit species-specific metabolic and behavioral responses to ovariectomy. Gen Comp Endocrinol 2010; 166: 520-528.
15. Rogers NH, Perfield II, JW, Strissel KJ, Obin MS, Greenberg AS,. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology 2009; 150: 2161-2168.
16. Gorzek JF, Hendrickson KC, Forstner JP, Rixen JL, Moran AL, Lowe DA,. Estradiol and tamoxifen reverse ovariectomy-induced physical inactivity in mice. Med Sci Sports Exerc 2007; 39: 248-256.
17. Revilla R, Revilla M, Villa LF, Cortes J, Arribas I, Rico H,. Changes in body composition in women treated with gonadotropin- releasing hormone agonists. Maturitas 1998; 31: 63-68.
18. Yamasaki H, Douchi T, Yamamoto S, Oki T, Kuwahata R, Nagata Y,. Body fat distribution and body composition during GnRH agonist therapy. Obstet Gynecol 2001; 97: 338-342.
19. Day DS, Gozansky WS, Van Pelt RE, Schwartz RS, Kohrt WM,. Sex hormone suppression reduces resting energy expenditure and {beta}-adrenergic support of resting energy expenditure. J Clin Endocrinol Metab 2005; 90: 3312-3317.
20. Sato M, Rippy MK, Bryant HU,. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996; 10: 905-912.
21. Tommaselli GA, Di Carlo C, Di Spiezio Sardo A, et al. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene. Menopause 2006; 13: 660-668.
22. Francucci CM, Daniele P, Iori N, Camilletti A, Massi F, Boscaro M,. Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. J Endocrinol Invest 2005; 28: 623-631.
23. Cucinelli F, Paparella P, Soranna L, et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 1999; 140: 215-223.
24. O'Sullivan AJ, Ho KKY,. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 1783-1788.
25. Saglam K, Polat Z, Yilmaz MI, Gulec M, Akinci SB,. Effects of postmenopausal hormone replacement therapy on insulin resistance. Endocrine 2002; 18: 211-214.
26. Duncan AC, Lyall H, Roberts RN, et al. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 1999; 84: 2402-2407.
27. Kimmerle R, Heinemann L, Heise T, et al. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 1999; 6: 36-42.
28. Ryan AS, Nicklas BJ, Berman DM,. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 2002; 25: 127-133.
29. Van Pelt RE, Gozansky WS, Schwartz RS, Kohrt WM,. Intravenous estrogens increase insulin clearance and action in postmenopausal women. Am J Physiol Endocrinol Metab 2003; 285: E311-E317.
30. Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998; 21: 1589-1595.
31. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 1-9.
32. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB,. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992; 74: 1396-1400.
33. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
34. Cagnacci A, Paoletti AM, Zanni A, et al. Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 4117-4121.
35. Lee CC, Kasa-Vubu JZ, Supiano MA,. Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women. J Am Geriatr Soc 2003; 51: 683-688.
36. Shlipak MG, Chaput LA, Vittinghoff E, et al. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 2003; 146: 870-875.
37. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA,. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. Arch Intern Med 2005; 165: 510-515.
38. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998; 97: 979-986.
39. Shaw K, Gennat H, O'Rourke P, Del Mar C,. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006: CD003817.
40. Katzel LI, Bleecker ER, Colman EG, Rogus EM, Sorkin JD, Goldberg AP,. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial. JAMA 1995; 274: 1915-1921.